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Progressive microglial accumulation at amyloid-b (Ab) plaques is a well-established signature of the
pathology of Alzheimer’s disease, but how and why microglia accumulate in the vicinity of Ab plaques is
unknown. To understand the distinct roles of Ab on microglial accumulation, we quantified microglial
responses to week-long lasting gradients of soluble Ab and patterns of surface-bound Ab in microfluidic
chemotaxis platforms. We found that human microglia chemotaxis in gradients of soluble Ab42 was most
effective at two distinct concentrations of 23 pg.mL
21 and 23 ng.mL
21 Ab42 in monomers and oligomers.
We uncovered that while the chemotaxis at higher Ab concentrations was exclusively due to Ab gradients,
chemotaxis at lower concentrations was enhanced by Ab-induced microglial production of MCP-1.
Microglial migration was inhibited by surface-bound Ab42 in oligomers and fibrils above 45 pg.mm
22.
Better understanding of microglial migration can provide insights into the pathophysiology of senile
plaques in AD.
M
icroglialcellsareresidentmacrophagesinthecentralneuralsystem(CNS)andhavemultiplefunctionsin
normal and pathological brains
1–6. Ramified microglia are believed to constantly scan the brain and clear
the CNS oftoxic agents and debris
7,8. In the contextof Alzheimer’sdisease (AD), diminished clearance of
Ab due to impaired microglia is postulated to be one of the mechanisms of Ab plaque formation
9.O n c eAb forms
plaques, microgliabecome hyper-activated
10, accumulatearound the plaques, and consequently secreteneurotoxic
agents including neuroinflammatory mediators, reactive oxygen species, and free radicals
11–14. Understanding the
mechanisms that lead to microglial accumulation and inflammatory responses may provide useful insights into
developing strategies for AD treatment. However, several studies report different interactions between microglia
and other factors
15–17.P r e v i o u sin vivo studies of microglia migration were hampered by both the inability to
observe long-term effects of Ab on microglia
18 and the complexity of senile plaques, which are deposits of
oligomeric and fibrillar Ab, surrounded by a ‘‘halo’’ of soluble oligomeric Ab
19, activated glia, and dystrophic
neurites
12. Activated microglial cells take on various morphologies: rounded, ramified shapes, rods to amoeboids,
which complicate the visual tracking of these cells individually. Furthermore, previous in vitro attempts to study
rat microglia migration in the presence of short lived, damaged axons
20, could not establish long-lasting gradients
and were not conclusive for differentiating slow accumulation of microglia from random navigation
21,22.
Here, wehave developed anovel microfluidic chemotaxis platform to study the motility of microglia respond-
ing to various types of Ab in a regulated manner. The new platform models soluble and bound Ab environments
in AD brains and enables us to measure the distinct effects of both gradients of soluble Ab, lasting longer than a
week and surface-bound patterns of Ab on the migration of microglia.
Results
A microfluidic platform provides a gradient of soluble Ab and allows monitoring of microglial motility.
Based on in vivo observation of microglial accumulation on Ab plaques, we hypothesize that soluble Ab is an
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SCIENTIFIC REPORTS | 3 : 1823 | DOI: 10.1038/srep01823 1effective stimulus in recruiting microglia, while insoluble, surface-
bound Ab can capture the attracted microglia at the sites of surface-
bound Ab (Fig. 1a). To understand how microglial migration is
regulated by Ab in AD, we designed a unique microfluidic chemo-
tactic platform composed of a large central reservoir (100 mL)
supplying various types of soluble factors and two side reservoirs
(100 mL each) containing medium. Human microglia were loaded
in the annular (4 mL) compartment and their migration was obser-
vedtowardsthecentral(1 mL)compartment(Fig.1b–c).Thecentral
andannularcompartmentswerelinkedbymigrationchannels(103
50 3 500 mm
3 in height, width, and length) forming gradients of
soluble factors. Compared to a parallel configuration having equal
surface areas for cell loading and cell collection, our axisymmetric
configuration has a small central cell collecting compartment, which
is smaller than a large annular cell loading compartment by a factor
of 6. This enhances detection of recruitment. The long and thin
migration channels can screen out unwanted entrance of inacti-
vated microglia through mechanical constraints. Using this plat-
form, we observed the migration of microglial cells, at single cell
resolution, in real-time, for extended periods (Fig. 1d). We verified
that refreshing media every two days allowed our experimental
conditions to have a reasonable degree of physical and chemical
stability of soluble Ab forms: 90 and 95% of original Ab gradients
of monomeric and oligomeric soluble Ab for up to nine days
(Supplementary Fig. S1), 74 and 84% of the total amounts of mono-
meric and oligomeric Ab solutions for two days (Supplementary
Fig. S2). Thus, for most experiments, we refreshed media includ-
ing soluble factors every two days. To evaluate the response of
microglia to various types of Ab, we tested 200 independent condi-
tions at the same time, by imaging microglia in 8 plates, each with
twenty-five platforms in an array format (Supplementary Fig. S3).
Directional migration of microglia towards soluble Ab. To
characterize the kinetics of microglial migration driven by soluble
Ab, we monitored individual microglial cells exposed to stable
gradients of soluble Ab for four days using time-lapse microscopy.
We observed that in the first 24 hours after introducing soluble Ab42
into a reservoir, microglia changed shape, became more elongated,
and produced filopodia in random directions (Fig. 2a, Supplemen-
tary Movies S1). However, most of the cells remained stationary for
the first 24 hours. Microglia started migrating on the second day of
exposure to soluble Ab42 and migration was directional towards the
soluble Ab42 reservoir (Fig. 2b). In the absence of soluble Ab42,
microglia expanded their bodies but did not migrate during four-
day experiments (Supplementary Movies S2). We measured com-
parable effects of monomeric and oligomeric forms, and measured a
maximal migration speed of 5.1 6 4.2 mm.hr
21 at 23 ng.mL
21
soluble monomeric Ab42 (Fig. 2c). We observed that microglia also
entered the central compartment, the source of 2.3 ng.mL
21 soluble
Ab42 monomers (Fig. 2d). Additional quantification of the effect of
soluble Ab on cellular distribution was performed by analyzing the
changes in cellular density profile over time (Fig. 2e).
Figure 1 | Replication ofAD-Ab environmentina microfluidic chemotaxis platform. (a)Wehypothesizethat at earlystages microglia arerecruited by
soluble Ab (sAb) (left) and at late stages co-localized with surface-bound Ab (bAb) near Ab plaques and neurons in AD brains (right).
(b), (c) A microfluidic chemotaxis platform models the pathological Ab environments in AD brains and provides surface-bound Ab inside the central
compartment(CC)andgradientsofsolubleAbbetweenthe CCandthe annularcompartment (AC),alongmigrationchannels(MC).Theaxisymmetric
configuration enhances the microglia counting during Ab recruitment and the long and thin migration channels help avoid counting errors due to
spontaneous migration. (d) Fluorescent images show human microglia (red) inside the AC and soluble Ab (light green) and patterned bAb (dark green)
insidetheCC.MicrogliamoveinagradientofsAbbetweenACandCC,alongtheMC(left-lowerinset).MicrogliaandbAbco-localizeintheCCaftersix
days (right-upper inset). Scale bars, 200 mm.
www.nature.com/scientificreports
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trations on microglial recruitment, we defined a recruitment index,
R.I. (as defined in Supplementary Methods, Supplementary Fig.
S7), representing the fraction of microglia cells recruited to the cent-
ral compartment after loading soluble Ab in the central compart-
ment. We compared the R.I. values under various types of soluble
Ab42 for eight days (Fig. 3a, Supplementary Fig. S4) and found that
the R.I. value reached 5.0 6 0.9 after exposure to monomeric syn-
thetic Ab42at 23 ng.mL
21 and 4.0 61.0 afterexposure to oligomeric
forms at 230 ng.mL
21, on ‘day 8’ (Fig. 3b). Measuring the concen-
tration dependence of directional migration speed and R.I. revealed
two peaks of activity at two concentrations of soluble Ab42 that were
three orders of magnitude apart (23 pg.mL
21 and 23 ng.mL
21)
(Fig. 2c and Fig. 3c). Interestingly, the low peak concentrations
corresponds to the levels in normal and early AD brains, while the
high peak to late AD brains
23.
Microglial recruitment by human-derived soluble Ab. To validate
the biological relevance of our platform, we measured the microglial
response to gradients of soluble Ab enriched or depleted samples
derived from tris-buffered saline (TBS) extracts of human AD
brains as previously described
24. For this purpose, low (8 to
20 kDa) and high molecular weight fractions (more than 100 kDa)
were separated by size exclusion chromatography (Fig. 3d). Both
low-molecular-weight soluble Ab (LMW) and high-molecular-
weight soluble Ab (HMW) fractions were similar in recruiting
microglia towards the central compartment on the eighth day (R.I.
5 3.7 6 0.5 for LMW and R.I. 5 3.9 6 0.6 for HMW) (Fig. 3e–f).
Removing the soluble Ab by immune-precipitation considerably
reduced the microglial accumulation (R.I 5 2.7 6 0.1 for LMW
and 2.7 6 0.7 for HMW), suggesting that a major factor of the
TBS extract inducing microglial migration was Ab.
Self-promoting microglial recruitment by Ab-induced MCP-1
secretion. Because typical chemotactic responses of various cells
display only one activity peak, we investigated further the
mechanisms behind the double peak chemotactic activities of
microglia in response to Ab. To probe if a second chemoattractant
may explain the unusual double chemotactic peak, we utilized a
multiplexed cytokine assay to examine 27 cytokines expressed into
the media collected from microglia cultured in the presence of
soluble Ab42 at 2.3 pg.mL
21 for two days. We identified five
cytokines at detectable levels: IL-1ra, IL-6, IL-8, MCP-1, and MIP-
1b while the remaining cytokines were either below, or just at
the threshold of detectability (Fig. 4a). Arrows indicate saturated
measurement of cytokines relative to the standard curve. Because
MCP-1, MIP-1a, and MIP-1b are known chemoattractant mole-
cules for macrophages
3,7,25, we measured microglial recruitment
under gradients of soluble Ab42 in addition to a mixture of
neutralizing antibodies against MCP-1, MIB-1a, and MIB-1b and
observed reduced activity at 23 pg.mL
21 but not at 23 ng.mL
21 of
soluble Ab42 (Fig. 4c). In control experiments, we validated that
MCP-1 alone can promote microglial recruitment and verified that
neutralizing antibodies can reduce microglial recruitment towards
the single cytokine (Fig. 4d). We further measured the MCP-1
concentration in media from microglia stimulated with various
concentrations of both monomeric and oligomeric soluble Ab42.
We estimated the maximum secretion of MCP-1 at 1,433.9 6
816.0 and 1,457.3 6 109.4 fg.cell
21 in the presence of 2.3 pg.mL
21
ofsolublemonomericandoligomericAb42,respectivelyand554.46
224.3 fg.cell
21 in the absence of soluble Ab42 (Fig. 4b). Interestingly,
the MCP-1 secretion in the presence of 2.3 pg.mL
21 Ab42 was
significantly higher than at other concentrations of Ab42 oligo-
mers. While the migration of microglia occurs at higher levels of
the gradient (23 pg.mL
21) than uniform Ab42 (2.3 pg.mL
21), the
difference could be explained by the lower effective concentration
attheinitialregionofagradient.ItispossiblethatMCP-1playsarole
inthepeakmicrogliarecruitmentactivityatagradientof23 pg.mL
21
soluble Ab42, in addition to other reported roles in microglia-
mediated neurodegeneration
26.
Figure 2 | Inducementof microglial directional migration by gradientsof soluble Ab. (a)Individual microglia migrate directionally along the gradient
of sAb monomers formed in migration channels. (b) Activation of directional motility can be discerned after 24 hours-exposure to gradients of sAb42 in
monomersat23 pg.mL
21and23 ng.mL
21.(c)Dose-dependenceofmicrogliamigrationspeedduring4daysobservationsrevealtwopeakactivitiesunder
gradients of soluble Ab42 monomers and oligomers at concentrations of 23 pg.mL
21 and 23 ng.mL
21 (ranges highlighted in cyan and pink colors,
respectively). (d) Fluorescence images present detectable microglia accumulation toward the source of soluble Ab42 at day 6 compared to day 0.
(e) Microglial density profiles at different days quantify the migration of microglia populations toward the source of soluble Ab42 in monomers at
2.3 ng.mL
21. See the details on the stability and the preparation of soluble monomeric and oligomeric Ab in Figs. S1, S2, and Supplementary methods.
(Student’s t-test. * P , 0.01 with respect to no sAb42). ncell 5 18 for each condition. Data represent mean 6 s.e.m.
www.nature.com/scientificreports
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surface. In AD brains, microglia presumably migrate towards
plaques, and then remain stably associated with the plaques. To
examine the mobility of microglia on surface-bound Ab,w e
prepared wells uniformly coated with surface-bound Ab42 fibrils
and tracked individual microglia cells moving on these surfaces
(Fig. 5a). We observed that the migration speed of microglia
decreased substantially from 26 to 2 mm.hr
21 with an increase of
surface-bound Ab42 concentration from 9 to 1,125 pg.mm
22, con-
sistent with the possibility that surface-bound Ab42 inhibited
microglial migration (Fig. 5b). We also observed some of the
microglia internalizing particles formed on Ab42 fibril–coated
surfaces, as well as dead cells (Supplementary Movies S3, S4). At
the same time, the viability of microglia decreased substantially on
highly concentrated surface-bound Ab42. Only 50% of microglia
remained viable at 1,125 pg.mm
22 after four days, suggesting acute
toxicity of surface-bound Ab fibrils to microglia.
MCP-1 secretion stimulated by surface-bound Ab. The level of
secreted MCP-1 was elevated also by bAb about two-fold (1,128.0
6 149.8 and 1,088.7 6 378.2 fg.cell
21 under Ab oligomers and Ab
fibrilsat9 ng.mm
22,respectively)compared towithoutAb(554.4 6
96.0 fg.cell
21)( Fig. 5c).
Microglial co-localization with patterned Ab. To further under-
stand how microglia target surface-bound Ab–rich plaques, we
patterned surface-bound Ab42 in both oligomeric and fibril forms
on wells at various concentrations by using PDMS stencils of 2 mm
holes (Fig. 5d, Supplementary Fig. S5). We quantified the co-
localization of microglia on the surface-bound Ab42 patterns by
calculating a localization index (L.I., defined in Supplementary
Methods, Supplementary Fig. S8), representing the amount of
localized cells on the patterned surface-bound Ab relative to the
day of microglia plating. We found that microglia co-localized
with surface bound Ab42 patterns at concentrations higher than
45 pg.mm
22. We measured a L.I. 5 1.4 6 0.1 with oligomers
and L.I. 5 1.9 6 0.5 with fibrils at 90 pg.mm
22 on the eighth day
(Fig. 5e–f).
Microglial recruitment and accumulation in the presence of
soluble and patterned Ab. To reconstruct the Ab microenviron-
ment analogous to that encountered by microglia near plaques, a
core of fibrillar Ab surrounded by a halo of soluble Ab likely
oligomers in the AD brains, we combined patterned surface-bound
Ab42 by using PDMS stencils of 1 mm holes and the gradient of
soluble Ab42 in the microfluidic platform (Fig. 5g, Supplementary
Fig. S6). The combination of a gradient of soluble Ab42 oligomers at
Figure 3 | Microglial recruitment using various soluble Ab. (a) Gradients of synthetic Ab42 monomers and oligomers are formed between Ab reservoir
and a microglia hosting annular compartment. (b) Significant recruitment of human primary microglia is measured in the presence of gradients of
synthetic sAb42. (c) Dose-dependence experiments quantified with a recruitment index, R.I. on a ‘day 8’, reveal peak activities under gradients of sAb42
monomers and oligomers at both concentrations of 23 pg.mL
21 and 23 ng.mL
21 compatible with measurement of a migration speed in Figure 2.
(d) Human sAb isextracted from AD brains in low and high molecular weights and forms gradients between Ab reservoir and a microglia hosting annular
compartment. (e), (f)Considerablerecruitmentofhuman primary microglia ismeasured along gradients ofhuman-derived sAb at a low molecularweight
(LMW) (e) and a high molecular weight (HMW) (f) Immune-depletion of sAb from the same human samples results in reduced microglial recruitment
effect. (Student’s t-test. * P , 0.1, ** P , 0.05 with respect to no sAb). nplatform 5 4a n dncell < 2,000 for each condition. Data represent mean 6 s.e.m.
www.nature.com/scientificreports
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22 achieved the
most effective localization by 2.5 times compared to 1.6 6 0.2 times
with surface-bound Ab42 fibrils at 90 pg.mm
22 only (Fig. 5h–i).
Discussion
Our study demonstrates that soluble monomeric and oligomeric Ab
serve as a ‘‘recruiting signal’’ and bound fibrillar and oligomeric
surface-bound Ab acts as a ‘‘targeting signal’’ during microglia
recruitment and localization. Together, soluble and insoluble Ab
have synergistic effects on microglial accumulation to sites of Ab
deposits, and could explain microglial accumulation in the vicinity
of Ab plaques in the AD cortex.
Moreover,theMCP-1dependentmechanismofmicrogliarecruit-
ment in response to lower doses of Ab may be important during
physiological neuroinflammation and could be relevant to the early
stages of microglial activation in AD. The microfluidic platform can
be extended to the study of migration of other cells relevant to the
progressionofneurodegenerativediseases
27,28,andcouldhelpquant-
ify the potency of various cytokines and chemokines, which have
been detected in the brain alone and in combinations
11, in modulat-
ing microglia recruitment and accumulation. With high-throughput
capabilities and regulated microenvironments, our platforms can
facilitate systematic monitoring of microglial migration and its
modulation by compounds for the treatment of neuroinflammation
in various disease conditions, including Alzheimer’s disease.
Methods
Microfluidic platform fabrication. Negative photoresists, SU-8 50 and SU-8 100
(MicroChem, Newton, MA, USA), were sequentially patterned using standard
lithographyona4’’siliconwafertocreateamoldforcellmigrationchannelsof50 mm
inheightandchemokinecompartmentsof100 mminheight.Amixtureofabaseand
a curing agent with a 1051 weight ratio (SYLGARD 184 A/B, Dowcorning, Midland,
MI, USA) was poured onto the SU-8 mold and cured for one hour at room
temperature under vacuum and, subsequently, cured for more than 3 hours in an
oven at 80uC. The cured polydimethyl-siloxane (PDMS) replica was peeled off from
the mold and holes were punched for fluid reservoirs. Arrayed holes were also
laser-cut (Zing 24, Epilog Laser, Golden, CO, USA) into a thin PDMS membrane of
250 mm in thickness (HT 6240, Bisco Silicones, Elk Grove, IL, USA) and an acrylic
plate of 6 mm in thickness. The machined membrane and the plate were glued
together using uncured PDMS and incubated at 80uC overnight. This assembly was
irreversibly bondedfirst tothePDMSreplica using oxygen plasmaat 50 mW, 5 ccm,
for 30 seconds (PX-250, March Plasma Systems, Petersburg, FL, USA), and later to a
glass-bottomedUniWellplate(MGB001-1-2-LG,MatricalBioscience,Spokane,WA,
USA). Immediately after the bonding, 10 mL of poly (l-lysine) solution (PLL, M.W.
70,000–150,000, 1.0 mg.mL
21, Sigma-Aldrich Co. LLC, St. Louis, MO, USA) was
injected into the each platform and incubated for 2 hours at a room temperature to
promote cellular adhesion. PLL-treated surface was rinsed with autoclaved and
0.2 mmfilteredwater(AM9920,LifeTechnologies,GrandIsland,NY,USA)andthen
Figure 4 | MCP-1secretionfrommicrogliaunderstimulationofsolubleAbandself-promotedmicroglialrecruitment. (a)Microglialcellsarecultured
in wells containing sAb42 and discernibly expressed five cytokines (MCP-1, MIP-1b, IL-ra1, IL-6, and IL-8) are measured among tested twenty-seven
human cytokinesfromextractedsolutions. (b)Highest levelsofacytokine, MCP-1are measuredwhenmicroglia are culturedunder sAb42inmonomers
andoligomersat2.3 pg.mL
21.(c)Microglialcellsareculturedinthepresenceofgradientsofcytokine-neutralizingantibody(Ab)combinedwithsAb42or
cytokines and reduction of recruitment index is measured in the presence of neutralizing antibody against MCP-1 and sAb42 at 23 pg.mL
21 but not
23 ng.mL
21. (d) MCP-1 is validated to be a potent chemoattractant for microglia and the recruitment is inhibited by immune-neutralization of MCP-1.
However, MIP-1a and MIP-1b have no microglial chemoattractant activity in this assay. (Student’s t-test. *P , 0.01 for oligomers with respect to no
sAb42). nwell 5 3, ncell < 2,000 in ‘(a)’, ‘(b)’ and nplatform 5 4, ncell < 2,500 in ‘(c)’, ‘(d)’ for each condition. Data represent mean 6 s.e.m.
www.nature.com/scientificreports
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supplemented with 5% FBS (Invitrogen, Grand Island, NY, USA), 10 ng.mL
21 of M-
CSF (AF-300-25, PeproTech Inc., Rocky Hill, NJ, USA), 25 mg.mL
21 of gentamicin
(G1397, Sigma-Aldrich), and 2.5 mg.mL
21 of amphotericin (A2411, Sigma-Aldrich).
Cell preparation. Human microglial cells (HMG 030, Clonexpress, Inc.,
Gaithersburg, MD, USA) were isolated initially as a free-floating population of cells
from fetal brain tissue samples digested with collagenase and grown in a proprietary
medium for 1–2 weeks. Before the experiment, cells were washed using medium
without serum and the cell membrane was labeled with red fluorescent dye
(PKH26PCL, Sigma-Aldrich). After centrifugation (400 g for 5 minutes), the cell
pellet was re-suspended in 1 mL of Diluent C (G8278, Sigma-Aldrich) and
immediately mixed with 4 mL of dye solution (P9691, Sigma-Aldrich) in 1 mL of
DiluentC.Thecell/dyemixturewasincubatedatroomtemperaturefor4minutesand
periodically mixed by pipetting in order to achieve a bright, uniform, and
reproducible labeling. After the incubation, the staining was stopped by adding an
equalvolume(2 mL)of1%BSAinPBSandincubatingfor1minutetoremoveexcess
dye. Unbound dye was washed by centrifuging and re-suspending the cells in the
culture medium. Finally, the stained microglia cells were suspended in the culturing
medium at the concentration of 1 M cells.mL
21.T e nmL of cell solution was injected
intoeachplatformand100 mLofaculturingmediumwasaddedintosideandcentral
extrawells.Theloaded cellswereincubated at37uCsupplied with5%CO2foratleast
Figure 5 | Microglial co-localization on surface-bound Ab alone and in combination with soluble Ab. (a) Microglial cells were cultured in wells
uniformly coated with bAb42 fibrils and tracked individually. (b) The bAb42 fibrils induce the simultaneous decrease of the mobility and the viability of
microglia, proportional to increased concentrations of the bAb fibrils. (c) The level of secreted MCP-1 is elevated by about two-fold on surfaces coated
withbAb42oligomersandbAb42fibrilsof9 ng.mm
22comparedtoanuncoatedsurface.(d)Fluorescentimagevisualizedco-localizedmicrogliainredon
aspotofbAb42fibrilsat90 ng.mm
22ingreen.Co-localizationofmicrogliaonthepatternedbAb42,becomesmoreeffectiveastheconcentrationincreases
with 1.5-fold enrichment on bAb42 oligomers (e) and 2-fold on bAb fibrils (f) at 90 ng.mm
22 on a ‘day 6’, respectively. (g) Fluorescent image visualized
co-localized microglia on bAb42 fibrils at 90 ng.mm
22 combined with sAb42 oligomers at 23 ng.mL
21 in a microfluidic platform. Co-localization
is 1.6-fold on bAb42 fibrils alone (h) compared to 2.5-fold on bAb42 fibrils at 90 ng.mm
22 in combination with a gradient of sAb42 oligomers at
23 ng.mL
21(i).Scalebars,1 mm.(Student’st-test.*P,0.1,**P,0.05withrespecttonobAb42).nwell52in‘(a)’,‘(b)’,‘(e)’,‘(f)’andnplatform52,ncell
< 2,000 in ‘(h)’, ‘(i)’ for each condition. Data represent mean 6 s.e.m.
www.nature.com/scientificreports
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media and Ab solutions were replaced every two days while collecting the used
solutions for Ab analysis.
Sourcing of human brain tissue. Brains from human subjects with a diagnosis of
Alzheimer’s disease were obtained through the Massachusetts Alzheimer’s Disease
Research Center. The Massachusetts Alzheimer’s Disease Research Center (ADRC)
serves, among other clinical and research activities, as a repository of samples from
patients with Alzheimer’s disease. ADRC clinical and research activities are reviewed
among others by the Institutional Review Board at the Massachusetts General
Hospital. Inaddition, the ADRC has a Certificate of Confidentiality issuedby the US
Department ofHealth &Human Services/NationalInstitutes ofHealth toprotectthe
privacy of individuals who are enrolled in this research against forced disclosure in
anycivil,criminal,administrative,legislativeorotherproceeding,eitheratthefederal,
state of local level. The human samples used in this study were anonymised. The
Institutional Review Board at the Massachusetts General Hospital viewed the use of
anonymized autopsy material for biochemistry assays as exempt from review.
Ab extraction from human brain tissues. Cortical gray matter from frontal lobe of
AD patient brains was homogenized in 5 volumes of TBSI (Tris-buffered saline with
protease inhibitor cocktail (Roche)) with 25 strokes on a mechanical Dounce
homogenizer and centrifuged at 260,000 3g for 30 min at 4uC. The supernatant was
used as a TBS-soluble fraction
28,29. 750 mL of TBS-soluble fraction of human brains
was separated by a size exclusion chromatography on double superdex 75 columns
(GE Healthcare Life Sciences, Piscataway, NJ, USA) in 50 mM ammonium acetate
pH 8.5 with an AKTA purifier 10
3,30. The individual fractions separated by SEC were
analyzed by immunoblotting and Ab specific sandwich ELISA and fraction 6 to 9
(.100 kDa)wasusedasaHMWAbandfraction30to33(20,8 kDa)wasusedasa
LMW Ab
30. Immediately after the size-exclusion chromatography, we removed
soluble Abincluding soluble alpha Abprecursor protein (APP) from the fractions by
immune-depleting with 6E10 antibody (Signet, Dedham, MA, USA).
Time-lapse imaging.For continuoustime-lapse imaging totrack individual cells, we
kept the UniWell plate on a fully automated microscope (Eclipse Ti, Nikon Inc.,
Melville, NY, USA) integrated with a heated incubating stage (LiveCell 05-11-0032
Rev B, Pathology Devices Inc., Westminster, MD, USA), which was set at 37.7uC, 5%
CO2,and85%humidity. Weimagedcellsatevery1-hour(NISElements,NikonInc.)
using a bright field and every 6-hour using a TRITC fluorescence microscope for 4
dayswitha103objectivelensandaperfectfocusingsysteminaphasecontrastmode.
For continual time-lapse imaging to count cells, we kept the plate in an incubation
chamber set at 37.7uC and 5% CO2 and then imaged it using 43 objective lens in a
large-area mode of 8 3 8m m
2 with a 15% stitching, a phase contrast mode, and a
TRITC fluorescent microscope every two–three days for seven days. For continual
time-lapse imaging to monitor gradient stability, we kept the plate at room
temperatureinadarkroom,andimagedusing43objectivelensinalarge-areamode
of 12 3 10 mm
2 without stitching, a phase contrast mode, and a TRITC fluorescent
microscope every two–three days for nine days.
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